Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$37.17 USD
+0.81 (2.23%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $37.13 -0.04 (-0.11%) 7:12 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CLDX 37.17 +0.81(2.23%)
Will CLDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLDX
Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Other News for CLDX
Jasper Therapeutics initiated with bullish view at Stifel, here's why
First Week of CLDX February 2025 Options Trading
Stifel starts Celldex at buy, sees lead drug as potential blockbuster
Buy Rating on Celldex’s Barzolvolimab: A Potential Best-in-Class Biologic for Chronic Spontaneous Urticaria
Celldex initiated with bullish view at Stifel, here's why